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Abstract
 
Langerhans cell histiocytosis (LCH) is characterized by a clonal proliferation and retention of
cells with a Langerhans cell (LC)-like phenotype at various sites within the body. The present
study set out to elucidate whether aberrant expression of chemokine receptors or dysregulation
of chemokine production in LCH lesions could explain abnormal retention of these cells.
Immunohistochemical analysis on 13 LCH biopsies of bone, skin, and lymph node all ex-
pressed the immature dendritic cell (DC) marker CCR6 on the lesional LCs and absence of the
mature DC marker CCR7. Furthermore, regardless of the tissue site, LCH lesions markedly
overexpressed CCL20/MIP-3
 
 
 
, the ligand for CCR6. The lesional LCs appeared to be the
source of this CCL20/MIP-3
 
 
 
 production as well as other inflammatory chemokines such as
CCL5/RANTES and CXCL11/I-TAC. These may explain the recruitment of eosinophils
and CD4
 
 
 
CD45RO
 
  
 
T cells commonly found in LCH lesions. The findings of this study em-
phasize that, despite abundant TNF-
 
 
 
, lesional LCs remain in an immature state and are in-
duced to produce chemokines, which via autocrine and paracrine mechanisms cause not only
the retention of the lesional LCs but also the recruitment and retention of other lesional cells.
We postulate that the lesional LCs themselves control the persistence and progression of LCH.
Key words: dendritic cell • migration • retention • inﬂammatory signalling • differentiation
 
Introduction
 
Langerhans cell histiocytosis (LCH), a rare disorder often
presenting during childhood, is uniquely characterized by a
clonal proliferation of CD1a
 
 
 
 dendritic Langerhans cells
(LCs; reference 1). Signs and symptoms of LCH can be ex-
plained by the existence of the granulomatous lesions, not
only present in skin or lymph node, where LCs normally
reside, but also in many other sites like bone marrow, lung
and liver (2). Other inflammatory cells may also accumulate
within the lesions, such as eosinophils, T cells, and mac-
rophages. Particularly the described lesional “cytokine
storm” with LCH cells and T cells as major producers are
accountable for the more systemic symptoms like fever,
failure to thrive, as well as for the well-known sequellae
like osteolysis and fibrosis leading to organ dysfunction (3).
Despite the rarity of this disease, with an annual incidence
in the pediatric age range estimated at 2–5 per 10
 
6
 
/year,
studies on LCH should help contribute to our understand-
ing of human in vivo dendritic cell (DC) biology.
Due to the integral role that migration plays in the nor-
mal function and distribution of LCs as well as the other le-
sional cells, it seems possible that dysregulation of chemo-
kine production and/or chemokine receptor expression
plays a role in LCH. Chemokines have already emerged as
major regulators of DC migration (4–8). DC subsets ex-
press a distinct pattern of functional chemokine receptors at
different stages of their maturation. Immature DCs express
receptors for inflammatory chemokines such as CCR1,
CCR2, CCR5, CCR6, and CXCR1 which enable the re-
cruitment of immature DCs to sites of inflammation where
cognate ligands are produced. Maturation of DCs is associ-
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ated with the coordinated down-regulation of receptors for
inflammatory chemokines and the up-regulation of recep-
tors for constitutive chemokines such as CXCR4 and
CCR7. This results in the responsiveness of these cells to
lymphoid chemokines causing the migration of mature
DCs to draining lymph nodes where they are effective at
activating naive and central memory T cells (9, 10).
As well as responding to chemokines, DCs also produce
both constitutive and inflammatory chemokines depending
upon their stage of maturation. Immature DCs release
the constitutive chemokines CCL22/MDC and CCL17/
TARC (11). At early stages of maturation, DCs produce
high levels of inflammatory chemokines such as CCL20/
MIP-3
 
 
 
, CCL2/MCP-1, CCL3/MIP-1
 
 
 
, CCL4/MIP-
1
 
 
 
, CCL5/RANTES, CXCL8/IL-8, and CXCL10/IP-
10. These chemokines will help to recruit both circulating
immature DCs as well as other immune cell types to in-
flamed tissue (12). At later time points in DC maturation,
constitutive chemokines are selectively up-regulated in-
cluding CCL19/MIP-3
 
 
 
, CCL17/TARC, and CCL22/
MDC (13).
There is some evidence that the CD1a
 
 
 
 cells in LCH
are in an arrested state of activation and/or differentiation
and thus act like immature DCs (14–16). However, it re-
mains to be determined whether this arrest is also reflected
at the level of chemokine receptor expression. In addition,
abnormal chemokine receptor expression could explain
the aberrant accumulation of the LC-like cells in these le-
sions. Furthermore, dysregulated production of chemo-
kines by the CD1a
 
 
 
 LCH cells might lie at the bottom of
why various other inflammatory cell types accumulate in
these lesions.
In the present study we show that all lesional CD1a
 
 
 
LCH cells express CCR6 and not CCR7 confirming that
LCH cells are indeed of an immature phenotype. In addi-
tion these CD1a
 
 
 
 cells appear to be a major source of
CCL20/MIP-3
 
 
 
. Finally, evidence is presented that, al-
though other chemokines are present as well, T cells may
be recruited to and/or retained in the lesions using the
same CCR6-CCL20/MIP-3
 
 
 
 receptor–ligand pair.
 
Materials and Methods
 
Tissue.
 
Paraffin blocks of tissues from 13 patients with LCH
were identified by pathologists at Leiden University Medical
Center, which acts as a reference center for bone tumors. In all
cases the diagnosis was reviewed and confirmed by immunohis-
tochemistry for S100 and CD1a. All biopsies showed the pres-
ence of characteristic lesions containing histiocytes, macrophages,
lymphocytes, and eosinophil granulocytes. Nine of the specimens
were from bone in cases of ostotic LCH, two were from skin bi-
opsies in cases of isolated skin disease and two were from exci-
sional lymph node biopsies from patients with solitary lymph
node involvement.
 
Reagents.
 
Secondary antibodies were from DakoCytoma-
tion, and substrate chemicals were from Vector Laboratories.
Secondary immunofluorescent reagents were goat anti–mouse
and goat anti–rabbit isotype specific Alexa Fluor antibodies
(Molecular Probes).
 
Immunohistochemistry.
 
Paraffin sections were cut at 4 
 
 
 
m and
placed onto aminopropyltriethoxysilane coated slides. The sec-
tions were dried overnight at 37
 
 
 
C, dewaxed, and rehydrated.
Endogenous peroxidase was blocked using methanol/0.3% H
 
2
 
0
 
2
 
for 20 min. The sections were then subjected to heat mediated
antigen retrieval in a microwave using either citrate buffer (10
mM, pH 6.0) or EDTA buffer (1 mM, pH 8.0).
Primary antibodies were diluted in 1% BSA in PBS and incu-
bated overnight at room temperature in a humidity chamber.
The bound primary antibodies were detected using several ap-
proaches. Single staining with antibodies specific for chemokines
was detected enzymatically using either MouseEnvision or a rab-
bit anti–goat-HRP antibody followed by VECTOR NovaRed
detection. Double and triple staining with primary anti-chemo-
kine receptors in combination with cell-specific markers was de-
tected fluorescently using the relevant secondary goat anti–mouse
or goat anti–rabbit isotype-specific Alexa Fluor 488, Alexa Fluor
647, or Alexa Fluor 546 antibodies. To test the specificity of im-
munostaining, primary antibodies were omitted or replaced by an
isotype-matched control antibody. Under these conditions no
 
Table I.
 
Technical Details of Antibodies Used in Immunohistochemical Study
 
Antibody Clone Species/isotype Source Ag retrieval  Control
CCR6 53103.111 Mouse IgG2b R&D Systems Citrate Tonsil
CCR7 6B3 Mouse IgG1 EBioscience EDTA Lymph node
CCR7 2H4 Mouse IgM BD Biosciences Citrate Lymph node
CXCR3 1C6 Mouse IgG1 BD Biosciences Citrate Tonsil
CCL20 67310.111 Mouse IgG1 R&D Systems Citrate Tonsil
CCL5 21445.1 Mouse IgG1 R&D Systems Citrate Tonsil
CXCL11 Rabbit IgG PeproTech Citrate Tonsil
CD3 Rabbit IgG DakoCytomation Citrate Tonsil
CD4 1F6 Mouse IgG1 NovoCastra Citrate Tonsil
CD8 4B11 Mouse IgG1 NovoCastra Citrate Tonsil
CD45RO UCHL1 Mouse IgG2a DakoCytomation Citrate Tonsil
CD1a 1CA04 Mouse IgG1 Neomarkers Citrate SkinT
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positive cells were identified. In addition, sections of suitable tis-
sues were used as positive controls (Table I).
 
Immunogold Labeling.
 
To carry out double staining of CD1a
 
 
 
cells and chemokines, immunofluorescent staining of CCL20/
MIP-3
 
 
 
 was combined with immunogold labeling of CD1a
 
 
 
cells. As both primary antibodies were mouse IgG1, the anti–
human CCL20/MIP-3
 
 
 
 was applied after direct labeling with
Alexa Fluor 488 using a monoclonal antibody labeling kit (A-
20181; Molecular Probes). The first primary antibody, CD1a,
was diluted in 0.1% cationic BSA (Aurion) in PBS, and the incu-
bation was performed overnight at room temperature in a hu-
midity chamber. Prior to immunogold labeling, an incubation
step with 5% BSA (diluted in PBS) for 30 min was introduced to
block nonspecific labeling. The secondary immunoreagent, goat
anti–mouse IgG coupled to ultra small colloidal gold particles
(Aurion) was diluted 1:50 in 0.1% cationic BSA in PBS and the
conditions of incubation were 2 h at room temperature. After
rinsing several times with PBS followed by several washes in
MilliQ water silver enhancement was performed for 20 min at
room temperature. Slides were then washed again with MilliQ
water followed by several rinses in PBS. The second directly la-
beled fluorescent antibody, CCL20/MIP-3
 
 
 
, was diluted 1:25 in
PBS and incubated overnight on the sections at room tempera-
ture. The sections were mounted using Mowiol and then ana-
lyzed by confocal microscopy using a Carl Zeiss MicroImaging,
Inc. LSM 510 confocal fluorescence microscope in fluorescence
and brightfield mode.
 
Results
 
Accumulation of CCR6-expressing CD1a
 
 
 
 Cells in LCH
Lesions.
 
To investigate whether LCs in LCH lesions are
in an arrested state of activation and/or differentiation, the
expression of particular chemokine receptors known to be
characteristic of different stages of DC maturation, namely
CCR6 (marker of immature DCs) and CCR7 (marker of
mature DCs) were studied. For this analysis double immu-
nofluorescent staining of CD1a and CCR6 as well as CD1a
and CCR7 was performed. In all the LCH tissues studied
double staining of CCR6 and CD1a on the same cells was
consistently found irrespectively of the site of the lesion
(Fig. 1 A). In contrast, expression of CCR7 was not ob-
served on the CD1a
 
 
 
 cells in these lesions (Fig. 1 B).
 
Expression of CCL20/MIP-3
 
 
 
 by CD1a
 
 
 
 Cells in LCH
Lesions.
 
Due to the expression of CCR6 by CD1a cells in
LCH lesions the presence of its cognate ligand, CCL20/
MIP-3
 
 
 
, in the affected tissues was investigated. First, sin-
gle enzymatic staining for CCL20/MIP-3
 
 
 
 on normal
control skin was performed. As previously reported, the
epidermis showed weak CCL20/MIP-3
 
 
 
 expression by
keratinocytes (Fig. 2 A). However, the same staining pro-
cedure on LCH skin lesions revealed an increased level of
CCL20/MIP-3
 
 
 
 immunoreactivity, not only in the epi-
dermis but also in the dermal region (Fig. 2 B). This
marked expression of CCL20/ MIP-3
 
 
 
 staining was also
consistently found in LCH bone and lymph node lesions
(Fig. 2, C and D).
The pattern of CCL20/MIP-3
 
 
 
 staining displayed in
LCH lesions appeared to closely match the distribution of
the lesional CD1a
 
 
 
 cells. To evaluate CCL20/MIP-3
 
 
 
 ex-
pression by the lesional CD1a
 
 
 
 cells, a double staining was
performed using immunogold labeling followed by silver
enhancement to detect the CD1a
 
 
 
 cells in combination
with immunofluorescent staining for CCL20/MIP-3
 
 
 
. As
shown in Fig. 3 this immunostaining of LCH lesions con-
sistently showed expression of CCL20/MIP-3
 
 
 
 by CD1a
 
 
 
cells. Most of the CCL20/MIP-3
 
 
 
 up-regulation could
thus be attributed to the CD1a
 
 
 
 cells themselves.
 
Expression of Other Inflammatory Chemokines by Lesional
CD1a
 
 
 
 Cells.
 
To determine whether the recruitment of
various inflammatory cell types characteristic of LCH le-
Figure 1. Expression of CCR6 but not CCR7 by LCH CD1a  cells.
Immunofluorescence staining of a representative LCH bone lesion using
antibodies specific for CD1a (green), CCR6 (red), and CCR7 (red).
Double immunofluorescent staining shows that all the CD1a  cells are
positive for CCR6, which appear yellow in the merged image (A). In
contrast CCR7 is negative on the CD1a  cells (B). Original magnifica-
tion 400 .
Figure 2. High expression level of CCL20/MIP-3  in LCH lesions.
Immunohistochemistry was performed with an anti-hCCL20/MIP-3 
monoclonal antibody and NovaRed detection. CCL20/MIP-3  was
weakly expressed by epidermal keratinocytes in normal skin (A) in con-
trast to LCH skin lesions where CCL20/MIP-3  expression was greatly
up-regulated both in the epidermis and by cells infiltrating the dermis (B).
Similarly a high expression level of CCL20/MIP-3  was found in LCH
bone and lymph node lesions (C and D, respectively). Original magnifica-
tion 250 .T
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sions could be explained by the production of chemokines
by the CD1a
 
 
 
 cells, we investigated the expression of par-
ticular chemokines associated with the infiltration of other
lesional cells. Besides CCL20/MIP-3
 
 
 
, prominent expres-
sion of the inflammatory chemokines CCL5/RANTES
and CXCL11/I-TAC was found in all lesions studied. Sim-
ilar to the CCL20/MIP-3
 
 
 
 staining the pattern of CCL5/
RANTES and CXCL11/I-TAC expression appeared to
closely match the distribution of the lesional CD1a
 
 
 
 cells
(unpublished data). As eosinophils are an important infil-
trating population in LCH lesions, the expression of
CCL5/RANTES seems relevant as this chemokine is
known to be a potent activator of not only eosinophil che-
motaxis but also eosinophil effector function. CXCL11/I-
TAC on the other hand is a well-known chemotactic agent
for IL-2 activated memory T cells expressing CXCR3.
 
Accumulation of CCR6-expressing CD4
 
 
 
 T Cells in LCH
Lesions.
 
One other predominant cell type that infil-
trates LCH lesions is the T cell. To characterize these
cells further and to try to determine which of the prom-
inently expressed chemoattractants could explain their
presence, double and triple immunofluorescent staining
was performed. All LCH lesions studied showed a pre-
dominance of CD4
 
 
 
 T cells which also displayed a
memory/activated type as indicated by their CD45RO
 
 
 
expression (unpublished data). In addition, a large ma-
jority of these T cells expressed CXCR3, a chemokine
receptor specific for CXCL11/I-TAC, which is com-
monly expressed on activated T cells (unpublished data).
Due to the enhanced expression of CCL20/MIP-3
 
 
 
 in
the LCH lesions, expression of its cognate receptor
CCR6, on the infiltrating T cells was also investigated.
Triple immunofluorescent staining of LCH lesions for
CD3, CD4 and CCR6 clearly showed positive staining
of CCR6 on the T cell infiltrate (Fig. 4). Thus, both
CXCR3 and CCR6 may explain the presence and re-
tention of the lesional T cells through the aberrant up-
regulation of CCL20/MIP-3
 
 
 
 and CXCL11/I-TAC by
the CD1a
 
 
 
 cells.
 
Discussion
 
LCH is a disease characterized by the abnormal accumu-
lation and retention of cells with a LC-like phenotype at
various tissue sites. LCH cells do not acquire typical den-
dritic-like processes and their phenotype reflects only par-
tial maturation when compared with the normal DC life
Figure 3. Expression of
CCL20/MIP-3  by CD1a  cells
in LCH lesions. Immunohis-
tochemistry was performed using
antibodies specific for CD1a and
CCL20/MIP-3 . The CD1a
was detected by an immu-
nogold/silver method (black)
and the CCL20/MIP-3  by im-
munofluorescence (green). The
merged image shows the same
cells positive for CD1a and
CCL20/MIP-3 . Note: the ar-
row points to endothelial cells
expressing CCL20/MIP-3 .
Original magnification 400 .
Figure 4. Lesional CD4  T cells express CCR6. Triple immunofluo-
rescent staining on a representative LCH bone lesion for CD3 (red), CD4
(blue), and CCR6 (green). The intensity profile measured between the
arrows demonstrates on two representative cells the three different fluo-
rescent labels. Original magnification 500 .T
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cycle. Due to the integral role that migration plays in the
normal functioning of DCs at their distinct stages of matu-
ration we hypothesized that inappropriate expression and/
or function of chemokine receptors on the lesional CD1a
 
 
 
cells may help explain the pathophysiology of this disease.
As the presence of CD1a
 
 
 
 cells uniquely define these le-
sions it can be speculated that the accumulation of other le-
sional cells is secondary to that of the presence of aberrant
CD1a
 
 
 
 cells.
We demonstrate here that the lesional CD1a
 
 
 
 cells are
indeed in an immature state as defined by their expression
of the chemokine receptor CCR6. This finding is in keep-
ing with a previous report by Geissmann et al. (16) who
showed that LCH cells are immature LC-like DCs that ex-
press higher levels of CD68 and CD14 than normal LCs.
Furthermore, they express intracellular MHC class II, are
frequently negative for CD86 and DC-LAMP and have the
same allostimulatory activity as immature normal DCs.
Conversely, CCR7 expression, a chemokine receptor in-
dicative of DC maturation which localizes DCs in lym-
phoid organs by responding to CCR7 agonists, appeared to
be absent on the lesional CD1a
 
 
 
 cells. Despite the various
inflammatory stimuli present in LCH lesions, such as TNF-
 
 
 
,
which should induce the maturation of the LCs, the
CD1a cells do not lose their expression of CCR6 and do
not up-regulate CCR7 (17). Thus it would appear from
these findings that due to the fact that the lesional CD1a
 
 
 
cells have the intrinsic inability to fully differentiate and
mature they do not express the correct chemokine recep-
tors. Thereby, the lesional CD1a
 
 
 
 cells are prevented from
leaving their peripheral tissue sites and accumulate. Al-
though we cannot provide functional data due to the un-
availability of live lesional cells, we feel that lesional CD1a
 
 
 
cells remain sensitive to the ligand, CCL20/ MIP-3
 
 
 
. One
reason for this is that the CCR6 expression levels remain
high. Several mechanisms can occur which result in cellular
desensitization to chemokines. However, DCs appear to
regulate their responsiveness mainly by up and down-regu-
lating their expression levels of chemokine receptors (18).
Furthermore, there is evidence from the literature that in
pancreatic cancer, the tumor cells also coexpress the CCR6
receptor and its ligand CCL20/ MIP-3
 
 
 
. Although this is a
very different cell system, here there is no indication that
the receptor is desensitized (19).
Although it is now clear that lesional CD1a
 
 
 
 cells in
vivo remain in an immature state, it has been shown that in
vitro CD1a
 
 
 
 LCH cells could differentiate toward mature
DCs in response to CD40 triggering (16). This raises the
question then why in vivo are these CD1a
 
 
 
 cells not re-
sponding to inflammatory maturation signals, such as TNF-
 
 
 
which are abundantly expressed in LCH lesions? In the
present study it was also shown that CD1a
 
 
 
 cells are the
probable source of up-regulated CCL20/MIP-3  produc-
tion in all LCH lesions studied. It is now known that
CCL20/MIP-3  expression is under the direct control of
TNF-  signaling (20, 21). Thus, these appear to be con-
flicting observations which will require in vitro experi-
ments to elucidate whether the failure to up-regulate
CCR7 is due to a signaling defect by inflammatory cyto-
kines or due to conflicting cytokine signals e.g., IL-10 as
suggested by Geissman et al. (16) Evidence showing signal-
ing defects would be more supportive of an aberrant/ma-
lignant phenotype of the CD1a  cells underlying the dis-
ease which has been suggested by groups who have shown
clonality and proliferation to be present in LCH lesions
(22–24). Alternatively, conflicting signaling would be more
supportive of a reactive disease.
Although the etiology of LCH is not clear, certainly the
CD1a  cells are capable of maintaining and progressing the
disease. In the present study it was shown that lesional
CD1a  cells express not only CCL20/MIP-3  but other
inflammatory chemokines such as CCL5/RANTES and
CXCL11/I-TAC. These chemokines are the likely factors
responsible for the recruitment of other inflammatory cell
types characteristic of LCH lesions. Although the presence
of T cells in all LCH lesions is a striking feature, the mech-
anism by which these T cells are recruited has not so far
been addressed. Most of the T cells surround the lesions in
the reactive ‘rim’, however a few are present within most
active lesions (25). To date there has been little information
on the in situ characterization of these T cells. The present
study has now clearly shown that the T cells in LCH le-
sions mainly comprise CD4  CD45RO  T cells with very
few CD8  T cells. Furthermore, most of the lesional T
cells express CXCR3 which is known to be closely related
to cell-mediated immunity (Th1-type immune response).
This memory/activated phenotype found on the lesional T
cells fits with previous findings of CD154 on these cells
(26). Immunohistochemical analysis consistently detected
expression of the CCL20/MIP-3  receptor, CCR6, on
the infiltrating T cells in LCH lesions. This finding along
with the fact that it has already been shown that CCL20/
MIP-3  specifically attracts the memory subset of T cells in
vitro (27), strongly implicates CCL20/MIP-3  as an im-
portant chemoattractant responsible for T cell recruitment
in LCH lesions. Thus the lesional CD1a  cells, the proba-
ble source of CCL20/MIP-3  in the LCH lesions, are not
only causing their own recruitment and retention but that
of other inflammatory cells as well.
Although in the present study we concentrated on a lim-
ited set of chemokines and chemokine receptors, it is nota-
ble from our findings that regardless of the tissue site of the
lesion, the same chemokine and chemokine receptor pro-
file was found in bone, skin, and lymph node LCH. How-
ever, in light of the role of some chemokine receptors as
tissue-specific homing molecules, it will be interesting to
determine whether other chemokine receptors expressed
by the CD1a  cells specifically determine the anatomical
localization of LCH lesions. It will be important to study
this not only in single isolated lesions but also in patients
with disseminated LCH where multiple sites are affected.
So far though our results indicate that any future interven-
tion strategies based on chemokines or their receptors will
be applicable to all LCH lesions.
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